Online inquiry

IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10079MR)

This product GTTS-WQ10079MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10079MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14660MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ2323MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ4730MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ529MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ11485MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ12437MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ14887MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ10636MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW